Pluri Inc.
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. It develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. The company's product candidates include PLX-PAD,… Read more
Market Cap & Net Worth: Pluri Inc. (PLUR)
Pluri Inc. (NASDAQ:PLUR) has a market capitalization of $26.34 Million ($26.34 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #28084 globally and #9377 in its home market, demonstrating a -1.52% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pluri Inc.'s stock price $3.23 by its total outstanding shares 8155948 (8.16 Million).
Pluri Inc. Market Cap History: 2015 to 2026
Pluri Inc.'s market capitalization history from 2015 to 2026. Data shows change from $737.30 Million to $26.34 Million (-30.44% CAGR).
Index Memberships
Pluri Inc. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.00% | #736 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #2360 of 3165 |
Weight: Pluri Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Pluri Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Pluri Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
18.25x
Pluri Inc.'s market cap is 18.25 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $933.04 Million | $2.85 Million | -$23.25 Million | 327.73x | N/A |
| 2018 | $514.22 Million | $50.00K | -$26.13 Million | 10284.32x | N/A |
| 2019 | $257.08 Million | $54.00K | -$35.31 Million | 4760.66x | N/A |
| 2020 | $461.30 Million | $23.00K | -$29.15 Million | 20056.54x | N/A |
| 2022 | $61.34 Million | $234.00K | -$41.24 Million | 262.13x | N/A |
| 2023 | $37.81 Million | $287.00K | -$28.32 Million | 131.75x | N/A |
| 2024 | $34.87 Million | $326.00K | -$20.89 Million | 106.95x | N/A |
| 2025 | $24.39 Million | $1.34 Million | -$22.58 Million | 18.25x | N/A |
Competitor Companies of PLUR by Market Capitalization
Companies near Pluri Inc. in the global market cap rankings as of March 19, 2026.
Key companies related to Pluri Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Pluri Inc. Historical Marketcap From 2015 to 2026
Between 2015 and today, Pluri Inc.'s market cap moved from $737.30 Million to $ 26.34 Million, with a yearly change of -30.44%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $26.34 Million | +8.03% |
| 2025 | $24.39 Million | -30.06% |
| 2024 | $34.87 Million | -7.79% |
| 2023 | $37.81 Million | -38.36% |
| 2022 | $61.34 Million | -35.61% |
| 2021 | $95.26 Million | -79.35% |
| 2020 | $461.30 Million | +79.44% |
| 2019 | $257.08 Million | -50.01% |
| 2018 | $514.22 Million | -42.89% |
| 2017 | $900.42 Million | -3.50% |
| 2016 | $933.04 Million | +26.55% |
| 2015 | $737.30 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Pluri Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $26.34 Million USD |
| MoneyControl | $26.34 Million USD |
| MarketWatch | $26.34 Million USD |
| marketcap.company | $26.34 Million USD |
| Reuters | $26.34 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.